Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of AMG 301 for migraine prevention
2017-000630-57Phase 2Completed
- Sponsor
- Amgen
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in migraine comparing AMG 301 with Placebo (2 arms). Primary endpoint: Change from baseline in mean monthly migraine days. Started Jun 2017; status: completed.
02
Drugs
zelminemab
03
Conditions
migraine
Beyond the preview
Go deeper on 2017-000630-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000630-57.